ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Health Care"

  • Abstract Number: 0261 • ACR Convergence 2024

    Clinical Implications, Bacterial Profiles, and Patient Outcomes in Hospitalized Patients with Autoimmune Rheumatic Diseases

    Angel Kevin Garza-Elizondo1, Ana Cecilia Bardan-Inchaustegui2, Pablo Gamez-Siller3, Diana Elsa Flores-Alvarado4, Jorge Esquivel-Valerio5, Jesus Cardenas-de la Garza2, Elsa Catalina Davila-Correa6, Alejandra Jacquelin Osuna-Corrales6, Karla Judith Duran-Villarreal6, Daniela Alejandra Salcedo-Soto7, Derek de Jesus Gauna-Leal6, Andrea Axelle Prado-Prado6, Debanhi Morales-Espronceda6, Nathalia Valdez-Benavides6, Nirvana Amairany González-Ontiveros6 and Dionicio Galarza-Delgado8, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, 2Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 3Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, 4Hospital Universitario Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico, 5Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, 6Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico, 7Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, 8UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Autoimmune rheumatic diseases (ARD) are chronic conditions that affect multiple organ systems. Patients with ARD tend to have a weak immune system due to…
  • Abstract Number: 1286 • ACR Convergence 2024

    An Analysis of Diversity, Equity, and Inclusion Initiatives in US ACGME-accredited Adult Rheumatology Fellowship Programs

    Hamza Ali and Alysia Kwiatkowski, University at Buffalo, Buffalo, NY

    Background/Purpose: The ACR 2015 Workforce Study Report highlighted a lack of diversity within the workforce with 73.6% of Adult Rheumatology providers identifying as White, 15%…
  • Abstract Number: 2116 • ACR Convergence 2024

    Artificial Intelligence Classifier for Osteoporosis Detection from Chest Radiographs: Performance Evaluation and Literature Comparison with Quantitative Ultrasound

    Miso jang1 and Minjun Kim2, 1Promedius, inc., Seoul Chuk Hospital, Seoul, Republic of Korea, 2Promedius, inc., Seoul, Republic of Korea

    Background/Purpose: Osteoporosis is a common condition that often goes unnoticed until it results in fractures, significantly increasing morbidity and mortality rates. Recent advancements in deep…
  • Abstract Number: 0265 • ACR Convergence 2024

    Performance of Two Gout Remission Definitions in a Two-Year Randomized Controlled Trial of Nurse-led Care

    Dansoa Tabi-Amponsah1, Michael Doherty2, Aliya Sarmanova3, Weiya Zhang2, Sarah Stewart4, William Taylor5, Lisa Stamp6 and Nicola Dalbeth7, 1The University of Auckland, Auckland, New Zealand, 2Academic Rheumatology, School of Medicine, University of Nottingham; Pain Centre Versus Arthritis, University of Nottingham, Nottingham, United Kingdom, 3Roche Diagnostics International, Clinical Development and Medical Affairs, Nottingham, England, United Kingdom, 4Auckland University of Technology, Auckland, New Zealand, 5The University of Otago, Wellington, Wellington, New Zealand, 6University of Otago, Christchurch, Christchurch, New Zealand, 7University of Auckland, Auckland, New Zealand

    Background/Purpose: To compare the performance of the 2016 preliminary gout remission definition and a simplified gout remission definition in a clinical trial of nurse-led gout…
  • Abstract Number: 1338 • ACR Convergence 2024

    Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study

    Mohammad Movahedi1, Angela Cesta2, Xiuying Li2, Mark Tatangelo3 and Claire Bombardier3, and OBRI investigators, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2UHN, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with rheumatoid arthritis (RA) have approximately a twofold increased risk of developing herpes zoster (HZ) compared to the general population. This elevated risk is attributed…
  • Abstract Number: 2146 • ACR Convergence 2024

    Validation of the Simple Calculated Osteoporosis Risk Estimation and Osteoporosis Self-assessment Tool Among People Aging with HIV in Peru

    Joselito Malca-Hernandez1, Daniel Granda2, Ahmed Abdeen3, Yvett Pinedo4, Flor Gonzales5, Miguel Tapia6, Patricia Garcia7 and Evelyn Hsieh8, 1Yale School of Public Health, Department of Epidemiology of Microbial Diseases / School of Public Health- Universidad Peruana Cayetano Heredia, Epidemiology, STD, and HIV Unit, New Haven, CT, 2Universidad Peruana Cayetano Heredia, Facultad de Medicina Alberto Hurtado, Lima, Lima, Peru, 3Yale School of Medicine, Section of Rheumatology, Allergy and Immunology / Penn State College of Medicine, State College, New Haven, CT, 4Hospital Nacional Arzobispo Loayza, Department of Infectious Diseases, Lima, Peru, 5Ministry of Health of Peru, Department of Infectious Diseases, Lima, Peru, 6Ministry of Health, Department of Infectious Diseases, Lima, Peru, 7School of Public Health- Universidad Peruana Cayetano Heredia, Epidemiology, STD, and HIV Unit, Lima, Peru, 8Yale School of Medicine / VA Connecticut Healthcare System, West Haven, Connecticut, New Haven, CT

    Background/Purpose: The life expectancy of people living with HIV (PLWH) has improved notably since the advent of antiretroviral therapy (ART). However, studies have shown that…
  • Abstract Number: 0301 • ACR Convergence 2024

    Path to Diagnosis in Familial Mediterranean Fever (FMF)

    Sejla Karup1, Dila Polat2, Erengul Dincsoy2, Feyza Nur Azman2, Mahir Emir Cokrak2, Ertan Berkiten2 and Serdal Ugurlu3, 1Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 2Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Istanbul, Turkey

    Background/Purpose: Familial Mediterranean Fever (FMF) is a genetic disorder characterized by recurrent febrile episodes and inflammation, most commonly presenting with peritonitis, pleuritis, and arthritis. The…
  • Abstract Number: 1390 • ACR Convergence 2024

    One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)

    Luis Gomez-Lechon Quiros1, José Miguel Sequí-Sabater2, Amalia Rueda3, Costas Torrijo Nerea4, Carlos Valera-Ribera5, Juan Miguel López-Gómez6 and Antonio Alvarez-Cienfuegos7, 1Hospital Francesc de Borja, Valéncia, Spain, 2La Ribera University Hospital, Rheumatology Department, Gandía, Comunidad Valenciana, Spain, 3Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, 4Generalitat valenciana, Valencia, Spain, 5Hospital Doctor Peset, Valéncia, Comunidad Valenciana, Spain, 6Conselleria de Sanitat/Hospital Universitario de Elda, Elda, Comunidad Valenciana, Spain, 7Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects the joints and other parts of the musculoskeletal system. Early diagnosis and initiation of…
  • Abstract Number: 2216 • ACR Convergence 2024

    Additive Impact of Rheumatoid Arthritis and HBcAb+ on All-cause and Cardiovascular Mortality

    Leiyi Yang1, Bo Chen2, Qibing Xie3 and Geng Yin4, 1Sichuan University, Cheng Du Shi, Sichuan, China (People's Republic), 2Chenbo, Chendu, Sichuan, China, 3Department of Rheumatology and Immunology, Chengdu, Sichuan, China, 4Department of Rheumatology and Immunology, chengdu, China (People's Republic)

    Background/Purpose: Rheumatoid arthritis (RA) and hepatitis B both have a high incidence and significant health impacts, possibly sharing a pathogenic connection. Notably, a considerable proportion of…
  • Abstract Number: 0366 • ACR Convergence 2024

    Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study

    Koushan Kouranloo1 and Chris Wincup2, 1Internal Medicine Resident., London, United Kingdom, 2King's College Hospital, London, United Kingdom

    Background/Purpose: Clinicians are encouraged to consider patient preferences for offering face-to-face vs virtual consultations. This adaptability is particularly important to rheumatologists caring for patients with…
  • Abstract Number: 1402 • ACR Convergence 2024

    Addressing Unmet Needs in Cannabis and Hemp by Improving Knowledge and Data Collection

    Jahan Marcu1, Philip Molloy2, Kayla Pray3 and Teresa Simon4, 1Marcu Enterprises/ Physicians Research Center, Jersey City, NJ, 2Physicians Research Center,LLC, Carver, MA, 3Physicians Research Center,LLC, Farmingdale, NJ, 4Physicians Research Center,LLC, Toms River, NJ

    Background/Purpose: Cannabis and its derivatives are increasingly integrated into treatments for rheumatic diseases, yet there is a significant lack of evidence and systematic data collection…
  • Abstract Number: 2242 • ACR Convergence 2024

    A Cross-sectional Study on Predictors of COVID-19 Infection, Admission and Mortality and Effect of Immunomodulating Treatments in Rheumatoid Arthritis

    Mohammad Movahedi1, Elliot Hepworth2, Angela Cesta3, Xiuying Li3, Claire Bombardier4 and Sibel Aydin5, and OBRI investogators, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada, 3UHN, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Ottawa Hospital Research Institute, Ottawa, ON, Canada

    Background/Purpose: COVID-19 infection frequently leads to a cytokine storm, which has successfully been treated with some immunomodulating therapies according to observational studies. Interestingly, treatments investigated…
  • Abstract Number: 0375 • ACR Convergence 2024

    Patient Outcomes During the Implementation of a Patient Decision-Aid for a Diverse Population of Systemic Lupus Erythematosus: A Study in 15 U.S. Rheumatology Clinics

    Jasvinder Singh1, Larry Hearld2, Walter Chatham3, Sonali Narain4, Narender Annapureddy5, Diane Kamen6, Kimberly Trotter7, vikas Majithia8, Zineb Aouhab9, Swamy Venuturupalli10, Daniel Wallace11, rosalind Ramsey-Goldman12, Alfred Kim13, Maureen McMahon14, S. Sam Lim15, Kalpana Bhairavarasu16, Alexa Meara17, Kenneth Kalunian18 and Cathy Lee Ching19, 1Baylor College of Medicine, Birmingham, AL, 2University of Alabama at Birmingham (UAB), Birmingham, AL, 3University of Nevada, Las Vegas, Las Vegas, NV, 4Northwell Health, Great Neck, NY, 5Vanderbilt University Medical Center, Nashville, TN, 6Medical University of South Carolina, Charleston, SC, 7University of Chicago, Chicago, IL, 8University of Missisippi Medical Center (UMC), Jackson, MS, 9Loyola University Medical Center, Oak Brook, IL, 10Attune Health, Beverly Hills, CA, 11Cedars Sinai Medical Center, Studio City, CA, 12Northwestern University, Chicago, IL, 13Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 14UCLA David Geffen School of Medicine, Los Angeles, CA, 15Emory University, Atlanta, GA, 16Baylor College of Medicine, Sugar Land, TX, 17The Ohio State University Wexner Medical Center, COLUMBUS, OH, 18University of California San Diego, La Jolla, CA, 19UMMC, Jackson, MS

    Background/Purpose: To implement a self-administered patient decision-aid (PtDA) for lupus in outpatient clinics, assess its reach/penetration within each clinic, and examine patient outcomesMethods: An effective…
  • Abstract Number: 1606 • ACR Convergence 2024

    Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data

    Paul Dolin1, Anat Shavit1, Karina A. Keogh2, Jennifer Rowell3, Chris Edmonds4, James M. Eudicone5, Amanda M. Moore6, Melissa Wilson7, Kinwei A. Chan6, Thomas Peer8 and Stephanie Y. Chen9, 1BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, 3Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, 4Market Access and Pricing, AstraZeneca, Gaithersburg, MD, 5Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, 6TriNetX, Cambridge, MA, 7TriNetX, Durham, NC, 8TriNetX, Farmington, NY, 9BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by chronic necrotizing vasculitis. Conventional therapy (oral glucocorticoids [OGC] ± immunosuppressants), mepolizumab, and…
  • Abstract Number: 2273 • ACR Convergence 2024

    Time-Trends in Real-World Glucocorticoid Treatment Strategies in Patients with Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort(CATCH) Study

    Orit Schieir1, Marie-France Valois2, Louis Bessette3, Carter Thorne4, Gilles Boire5, Susan Bartlett2, Glen Hazlewood6, Carol Hitchon7, Diane Tin4, Hugues Allard-Chamard8, Bindee Kuriya9, Janet Pope10 and Vivian Bykerk11, and on behalf of CATCH Investigators., 1McGill University, Montreal, QC, Canada, 2Centre for Outcomes Research & Eval, Montreal, QC, Canada, 3University of Laval, Quebec City, QC, Canada, 4Newmarket Rheumatology Consultants, Newmarket, ON, Canada, 5Retired, Sherbrooke, QC, Canada, 6University of Calgary, Calgary, AB, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8University of Sherbrooke, Sherbrooke, QC, Canada, 9University of Toronto, Toronto, Canada, 10University of Western Ontario, London, ON, Canada, 11Hospital For Special Surgery, New York, NY

    Background/Purpose: Increased availability of a wider array of effective RA treatments and evidence of glucocorticoid (GC)-related adverse events have prompted updated recommendations limiting GC use…
  • 1
  • 2
  • 3
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology